@article {Calhoun741, author = {E. A. Calhoun and E. E. Welshman and C.-H. Chang and J. R. Lurain and D. A. Fishman and T. L. Hunt and D. Cella}, title = {Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group{\textemdash}Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy}, volume = {13}, number = {6}, pages = {741--748}, year = {2003}, doi = {10.1136/ijgc-00009577-200311000-00003}, publisher = {BMJ Specialist Journals}, abstract = {The purpose of this study was to validate the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group{\textemdash}Neurotoxicity (FACT/GOG-Ntx) questionnaire. The FACT/GOG-Ntx is the FACT-G plus an eleven-item subscale (Ntx subscale) that evaluates symptoms and concerns associated specifically with chemotherapy-induced neuropathy. Two groups of women with ovarian cancer completed the FACT/GOG-Ntx: one group with known neurotoxicities and one group of chemotherapy-naive women newly diagnosed with ovarian cancer. Levels of patient neuropathy, severity of toxicity, and patient quality of life from diagnosis of ovarian cancer to 12 months post-diagnosis were assessed. The Ntx subscale significantly differentiated the two groups at baseline and 3- and 6-month follow-ups, demonstrating significantly fewer problems among chemotherapy-naive patients than among patients with known neuropathy. The FACT/GOG-Ntx is a reliable and valid instrument for assessing the impact of neuropathy on health-related quality of life. The Ntx subscale demonstrated sensitivity to meaningful clinical distinctions and change over time.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/13/6/741}, eprint = {https://ijgc.bmj.com/content/13/6/741.full.pdf}, journal = {International Journal of Gynecologic Cancer} }